The importance of assessing blood tumour burden in cutaneous T‐cell lymphoma

por Vermeer, M.H., Nicolay, J.P., Scarisbrick, J.J., Zinzani, P.L.
Publicado 2021

PB1880: A MULTICENTER PHASE 1 STUDY EVALUATING THE SAFETY AND TOLERABILITY OF HMPL-760 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA O...

por Kahl, B., Cohen, J., Pillai, R., Jayaprakash, V., Wang, C., Hahka-Kemppinen, M., Kania, M., Zinzani, P.
Publicado 2022

First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi

por Broccoli, A., Argnani, L., Botto, B., Corradini, P., Pinto, A., Re, A., Vitolo, U., Fanti, S., Stefoni, V., Zinzani, P. L.
Publicado 2019

Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies

por Agostinelli, C, Piccaluga, P P, Went, P, Rossi, M, Gazzola, A, Righi, S, Sista, T, Campidelli, C, Zinzani, P L, Falini, B, Pileri, S A
Publicado 2008

PB1862: BRUIN CLL-313: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS BENDAMUSTINE+RITUXIMAB IN UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC L...

por Jurczak, W., Dartigeas, C., Coscia, M., Ganly, P., Al-Jazayrly, G., Wang, C., Bao, K., Leow, C. C., Shahda, S., Zinzani, P. L.
Publicado 2022

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study

por Zinzani, P. L., Vose, J. M., Czuczman, M. S., Reeder, C. B., Haioun, C., Polikoff, J., Tilly, H., Zhang, L., Prandi, K., Li, J., Witzig, T. E.
Publicado 2013

Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results

por Stefoni, V, Casadei, B, Bottelli, C, Gaidano, G, Ciochetto, C, Cabras, M G, Ansuinelli, M, Argnani, L, Broccoli, A, Gandolfi, L, Pellegrini, C, Zinzani, P L
Publicado 2016

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY

por Kuruvilla, J., Armand, P., Herrera, A. F., Ribrag, V., Brice, P., Thieblemont, C., Von Tresckow, B., Kim, E., Marinello, P., Chakraborty, S., Orlowski, R., Zinzani, P. L.
Publicado 2022

P1123: TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL)

por Vorobyev, V., Yoon, D. H., Kaźmierczak, M., Grosicki, S., Tarella, C., Genua, A., Kim, J. S., Cohan, D., Daugherty, M., Flinn, I. W., Zinzani, P. L., Gordon, L. I.
Publicado 2022

P1178: BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF T...

por Bartlett, N. L., Yasenchak, C. A., Ashraf, K. K., Harwin, W. N., Orcutt, J., Kuriakose, P., Zinzani, P. L., Mamidipalli, A., Fenton, K., Glenn, C., Nowakowski, G.
Publicado 2022

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CI...

por Hamadani, M., Coleman, M., Boccia, R., Duras, J., Hutchings, M., Zinzani, P. L., Cordoba, R., Oreiro, M. B., Williams, V., Stouffs, M., Langmuir, P., Sancho, J.-M.
Publicado 2022

PB2111: SUBGROUP ANALYSIS IN RE-MIND2, AN OBSERVATIONAL, RETROSPECTIVE COHORT STUDY OF TAFASITAMAB + LENALIDOMIDE VERSUS SYSTEMIC THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY DIF...

por Nowakowski, G. S., Yoon, D. H., Joffe, E., Zinzani, P. L., Sabatelli, L., Waltl, E. E., Alvero, C. G., Hess, G., Riedell, P., Kim, K., Brixner, D., Salles, G.
Publicado 2022

Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

por Jurczak, W, Zinzani, P L, Gaidano, G, Goy, A, Provencio, M, Nagy, Z, Robak, T, Maddocks, K, Buske, C, Ambarkhane, S, Winderlich, M, Dirnberger-Hertweck, M, Korolkiewicz, R, Blum, K A
Publicado 2018

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TR...

por Mato, A. R., Wierda, W. G., Pagel, J. M., Davids, M. S., Zinzani, P. L., Lu, Y., Liu, H., Shahda, S., Leow, C. C., Tam, C. S., Woyach, J. A., Eyre, T. A.
Publicado 2022

Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients

por Zinzani, P L, Fanti, S, Battista, G, Tani, M, Castellucci, P, Stefoni, V, Alinari, L, Farsad, M, Musuraca, G, Gabriele, A, Marchi, E, Nanni, C, Canini, R, Monetti, N, Baccarani, M
Publicado 2004

P1172: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS

por Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Jacobsen, E. D., Gritti, G., Pinter-Brown, L., Isutzu, K., Cohan, D., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., Horwitz, S. M.
Publicado 2022

Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression

por Oki, Y, Buglio, D, Zhang, J, Ying, Y, Zhou, S, Sureda, A, Ben-Yehuda, D, Zinzani, P L, Prince, H M, Harrison, S J, Kirschbaum, M, Johnston, P B, Shen, A, von Tresckow, B, Younes, A
Publicado 2014

Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial

por Cowan, R.A., Scarisbrick, J.J., Zinzani, P.L., Nicolay, J.P., Sokol, L., Pinter‐Brown, L., Quaglino, P., Iversen, L., Dummer, R., Musiek, A., Foss, F., Ito, T., Rosen, J‐P., Medley, M.C.
Publicado 2021

P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LAB...

por Herrera, A. F., Lavie, D., Johnson, N. A., Avigdor, A., Borchmann, P., Andreadis, C., Bazargan, A., Gregory, G., Keane, C., Inna, T., Vucinic, V., Zinzani, P. L., Zhang, H., Pillai, P., Marinello, P., Timmerman, J.
Publicado 2022

P1131: POST HOC ANALYSIS OF PATIENTS WITH HIGHLY PROLIFERATIVE VARIANTS OF MANTLE CELL LYMPHOMA TREATED WITH ACALABRUTINIB

por Le Gouill, S., Długosz-Danecka, M., Rule, S., Luigi Zinzani, P., Goy, A., Smith, S. D., Doorduijn, J. K., Panizo, C., Shah, B., Davies, A., Eek, R., Jacobsen, E., Kater, A. P., Robak, T., Jain, P., Calvo, R., Yang, H., Wang, M.
Publicado 2022